Baker Brothers Advisors - SYNDAX PHARMACEUTICALS INC ownership

SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of SYNDAX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2022$2,661,000
+24.9%
110,7290.0%0.02%
+41.7%
Q2 2022$2,130,000
+10.7%
110,7290.0%0.01%
+9.1%
Q1 2022$1,924,000
-20.6%
110,7290.0%0.01%
-8.3%
Q4 2021$2,424,000
+14.6%
110,7290.0%0.01%
+33.3%
Q3 2021$2,116,000110,7290.01%
Other shareholders
SYNDAX PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 1,932,800$33,592,00010.90%
Aisling Capital Management LP 1,025,000$17,815,0009.61%
Frazier Life Sciences Management, L.P. 3,195,403$55,536,0004.73%
Paradigm Biocapital Advisors LP 701,356$12,190,0003.22%
SPHERA FUNDS MANAGEMENT LTD. 1,277,413$22,201,0003.14%
Nantahala Capital Management 2,692,303$46,792,0002.07%
Avidity Partners Management LP 4,823,400$83,831,0001.75%
DAFNA Capital Management LLC 371,987$6,465,0001.68%
ACUTA CAPITAL PARTNERS, LLC 206,126$3,582,0001.67%
BVF INC/IL 2,394,714$41,620,0001.66%
View complete list of SYNDAX PHARMACEUTICALS INC shareholders